Proteon Pharmaceuticals today announced the completion of its latest investment round, which aims to accelerate commercialisation of its products in aquaculture and livestock farming, as well as to further develop its microbiome platform technology.
The financing round was led by the Polish Development Fund (PFR), Nutreco, and Aqua-Spark. Other investors in the round include Montis Capital and Seventure in addition to a group of angel investors.
As announced in January, Skretting’s collaboration with Proteon Pharmaceuticals is continuing, with the partners aiming to provide functional solutions to tackle health challenges in the aquaculture industry. The companies are co-developing products using bacteriophage technology to support farmers as part of a holistic health strategy.
Rob Koremans, Nutreco CEO says, “This investment underlines Nutreco’s commitment to our purpose of Feeding the Future and to the partnership between Proteon Pharmaceuticals and Nutreco’s aquaculture division Skretting. Our investment is a great next step to deepen this ongoing relationship and to support Proteon in this exciting phase in the company’s development.”
The facility has been built with an investment of EUR 18.5 million and will cater to domestic and export markets. It has three production lines with a capacity of 50,000 metric tonnes per annum.
Skretting’s second aquafeed factory in Vietnam opened in the Long An Province on 18 November. The investment aims to promote sustainable growth – to better serve and bring mutual benefits to its customers in the region.
